Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Azathioprine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.98 |
| ▸ | HBB | P68871 | 2/20 | 0.98 |
| ▸ | LMNA | P02545 | 2/20 | 0.98 |
| ▸ | TP53 | P04637 | 2/20 | 0.98 |
| ▸ | GMNN | O75496 | 1/20 | 0.98 |
| ▸ | PGR | P06401 | 1/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.98 |
| ▸ | BLM | P54132 | 1/20 | 0.98 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.98 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.98 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | NPC1 | O15118 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | GFER | P55789 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azathioprine SCHEMBL29693611 | 0.99 | MAPT (1.00) | MAPTHBBLMNATP53GMNN | |
| Azathioprine SCHEMBL4278 | 0.99 | MAPT (1.00) | MAPTHBBLMNATP53GMNN | |
| Azathioprine SCHEMBL4436347 | 0.99 | MAPT (1.00) | MAPTHBBLMNATP53GMNN | |
| Azathioprine SCHEMBL317904 | 0.98 | MAPT (0.98) | MAPTHBBLMNATP53GMNN | |
| Azathioprine SCHEMBL3089846 | 0.98 | MAPT (0.98) | MAPTHBBLMNATP53GMNN | |
| Azathioprine SCHEMBL26152 | 0.98 | MAPT (0.98) | MAPTHBBLMNATP53GMNN | |
| Azathioprine SCHEMBL4259183 | 0.91 | MAPT (0.84) | MAPTHBBLMNATP53GMNN | |
| Azathioprine SCHEMBL8354969 | 0.90 | MAPT (0.82) | MAPTHBBLMNATP53GMNN | |
| Azathioprine SCHEMBL8511946 | 0.90 | MAPT (0.82) | MAPTHBBLMNATP53GMNN | |
| Azathioprine SCHEMBL2328735 | 0.90 | MAPT (0.82) | MAPTHBBLMNATP53GMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190135931-A1 | COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC ANTIBODIES | NOVARTIS AG (CH) | 2019-05-09 | — | — | US | disclosed |
| US-20160347851-A1 | COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC ANTIBODIES | NOVARTIS AG (CH) | 2016-12-01 | — | — | US | disclosed |
| US-9382326-B2 | Compositions and methods of use for therapeutic antibodies | NOVARTIS AG (CH) | 2016-07-05 | — | — | US | disclosed |
| US-9340620-B2 | Compositions and methods of use for therapeutic antibodies | NOVARTIS AG (CH) | 2016-05-17 | — | — | US | disclosed |
| EP-2315780-B1 | COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC ANTIBODIES | NOVARTIS AG (CH) | 2015-08-19 | — | — | EP | disclosed |
| US-20120195913-A1 | COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC ANTIBODIES | NOVARTIS AG (CH) | 2012-08-02 | — | — | US | disclosed |
| US-20120183529-A1 | COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC ANTIBODIES | NOVARTIS AG (CH) | 2012-07-19 | — | — | US | disclosed |
| US-8106163-B2 | Compositions and methods of use for therapeutic antibodies | NOVARTIS AG (CH) | 2012-01-31 | — | — | US | disclosed |
| EP-2315780-A1 | COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC ANTIBODIES | Novartis AG (CH) | 2011-05-04 | — | — | EP | disclosed |
| US-20100021452-A1 | COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC ANTIBODIES | NOVARTIS AG (CH) | 2010-01-28 | — | — | US | disclosed |
| WO-2010007082-A1 | COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC ANTIBODIES | NOVARTIS AG (CH) | 2010-01-21 | — | — | WO | disclosed |